Penobscot Investment Management Company Inc. Makes New Investment in Invesco Biotechnology & Genome ETF $PBE

Penobscot Investment Management Company Inc. acquired a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,450 shares of the company’s stock, valued at approximately $1,892,000. Penobscot Investment Management Company Inc. owned about 0.45% of Invesco Biotechnology & Genome ETF at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. YHB Investment Advisors Inc. bought a new position in Invesco Biotechnology & Genome ETF during the third quarter worth about $2,169,000. Royal Bank of Canada increased its stake in shares of Invesco Biotechnology & Genome ETF by 25.9% in the 1st quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock valued at $4,698,000 after acquiring an additional 12,215 shares during the last quarter. Newman Dignan & Sheerar Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $912,000. Investment House LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $582,000. Finally, Dynamic Advisor Solutions LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter valued at approximately $484,000.

Invesco Biotechnology & Genome ETF Price Performance

Shares of NYSEARCA:PBE opened at $100.74 on Wednesday. The firm’s 50 day simple moving average is $96.64 and its 200 day simple moving average is $86.97. Invesco Biotechnology & Genome ETF has a fifty-two week low of $72.27 and a fifty-two week high of $100.74. The company has a market capitalization of $437.21 million, a price-to-earnings ratio of 20.44 and a beta of 0.70.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.